Gastrointestinal Oncology
Treatment options for patients with advanced gastrointestinal (GI) tumors are still very limited. Our research goal is the development and standardization of new and innovative therapeutic strategies for GI tumors, especially for hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA).Therefore, we are investigating novel systemic as well as locally ablative therapies in clinical trials (Phase I-III). Our research is focused on the molecular processes influencing and shaping cell proliferation, migration and metastasis. Better understanding of these regulatory mechanisms will lead to the development of novel therapeutic and diagnostic strategies.
You are here:
Wissenschaftliche Fragestellungen
- Biology of hepatocellular, cholangiocellular and neuroendocrine tumors
- Regulation of non-coding RNAs (miRNA, ncRNA) in gastrointestinal cancers
- Checkpoint Inhibitors for the treatment of HCC and CCA
- Locally ablative therapies for CCA treatment
- Role of pathogenic and prognostic Biomarkers in gastrointestinal cancers und in intensive care
Förderung
- German Research Foundation (DFG)
- Wilhelm Sander Foundation
- B. Braun Foundation
- Drittmittel des Deutschen Zentrums für Herz-Kreislauf-Forschung e.V. (DZHK)
- Industry funding
Klinische Studien
Investigator Initiated Trials (IIT):
- Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with CCC (TRITICC)
Clinical Trials:
- Study of adjuvant Nivolumab versus Placebo for participants with HCC Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (CA209-9DX)
- Study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage HCC (IMMUNIB)
- Trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage HCC (IMMULAB)
- A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with HCC (HCC-TARGET)
- Study of Nivolumab versus Sorafenib as first-line treatment in patients with advanced HCC (CA209-459)
- Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma (BGB-A317-301)
- A study of Atezolizumab in combination with Bevacizumab compared with Sorafenib in patients with untreated locally advanced or metastatic HCC (IMbrave150)
- Study of PD-1 Antibody SHR-1210 Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with Advanced HCC Who Have Not Previously Received Systemic Therapy (SHR-1210-III-310)
Leitung
Senior Physician GI Oncology & Gastroenterological-oncological day clinic W49T
